Danish Biotech Weekly – Week 18

Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc.

In the past week, CS Medica gave an update on their joint venture with RongShi, the CEO of 2CureX bought shares, and SynAct Pharma completed recruitment for its phase 2b study. 11 of the 20 listed, Danish biotech companies have published news the past week. 7 of the companies had a positive development in their share price for the week and 7 companies have had a positive share price performance year to date. Fluoguide tops chart of best performing stick this year.

Company news the past week

Ascendis Pharma

Ascendis Pharma Reports First Quarter 2023 Financial Results (LINK)

Biosergen

No news the past week

Cessatech

No news the past week

CS Medica

CS MEDICA Joint Venture, RongShi MEDICA (Ordos) Co. Ltd., update (LINK)

Curasight

No news the past week

Evaxion Biotech

Fourth quarter and full year 2022 financial results and business update (LINK)

Expres2ion

No news the past week

Fluoguide

No news the past week

Genmab

Genmab To File Appeal in Its Second Arbitration Under License Agreement with Janssen (LINK)

Gubra

Gubra announces the end of the stabilisation period (LINK)

Partial exercise of the overallotment option in connection with the initial public offering of Gubra increasing total offering size to 4,913,521 shares (LINK)

Initiator Pharma

No news the past week

IO Biotech

No news the past week

Pila Pharma

Pila Pharma AB publishes annual report for 2022 (LINK)

Pila Pharma AB publishes interim report (1 January – 31 March 2023) (LINK)

Saniona

Saniona publishes its Annual Report for 2022 (LINK)

Scandion Oncology

No news past week

SynAct Pharma

SynAct Pharma completes patient recruitment for Phase 2b EXPAND study of AP1189 in early severe Rheumatoid Arthritis (LINK)

ViroGates

No news past week

Zealand Pharma

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons (LINK)

Y-mAbs Therapeutics

Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023 (LINK)

2cureX

2cureX’s CEO Fernando Andreu purchases shares in the company (LINK)

SELECTED CASES

SHARE PRICE DEVELOPMENTS

There were mixed developments among the Danish Biotech stocks last week. The average return was -1,4%. 2CureX AB rose the most with 11% after their CEO bought shares. SynAct Pharma AB also performed nicely after they completed the recruitment for their Phase 2b EXPAND study of AP1189 in early severe Rheumatoid Arthritis. On the other hand, Biosergen AB and Evaxion Biotech A/S became the worst performing Danish biotech stocks last week. Since the start of the year, most of the companies have delivered a negative return. However, the average return year-to-date is positive at 2,1% because a few companies as especially Fluoguide AB and Saniona AB have done really well.

Read more about Fluoguide: The unique cancer treatment of the future – Today’s investment

Disclaimer 

Udvalgte investeringscases

Ønsker du at modtage et af vores nyhedsbreve? Udfyld venligst formularen nedenunder.

  • Investeringscases – Nyhedsbreve med top aktuelle investeringscases fra de nordiske vækstbørser og life science sektoren, og ugentlige markedsopdateringer..
  • Børsnoteringer – Opdateringer på nye og igangværende børsnoteringer i Skandinavien samt resultaterne af dem. (Nyhedsbrev fra Nyemission.dk)   
  • Nyheder – Nyheder fra og om Kapital Partner, herunder indsigt om kapitalmarkederne og børsnoteringer samt invitation til investormøder og- arrangementer.
  • Danish Biotech Weekly – Ugentlig opdatering med nyheder og kursudvikling for alle danske, børsnoterede selskaber uanset hvilket land eller børs de er noteret

*Hvis du ønsker information om vores kommende investeringsforening med fokus på de nordiske vækstbørser, herunder mulighed for at investere, så tilmeld dig nyhedsbrevet Nyheder.





Investornetværk:

Ønsker du at være en del af Kapital Partners investornetværk, hvor du får adgang til investeringer i selskaber og emissioner, samt indbydelse til investorrettede arrangementer
udfyld venligst formularen her.

Del indlægget på sociale media eller på email. 

LinkedIn
Facebook
Twitter
Email